The popular weight-loss medication Wegovy, developed by Novo Nordisk, is now more accessible in the United States as the company partners with telehealth providers such as Hims & Hers Health, Ro, and LifeMD. These collaborations come as the drug experiences a resurgence in availability after previous shortages.

Partnerships and Patient Access

These telehealth agreements aim to streamline the process for patients seeking Wegovy, allowing healthcare providers to prescribe the medication directly and facilitating home delivery. According to Dave Moore, the executive vice president of U.S. operations at Novo Nordisk, “We felt it was really important to work hard to establish a collaboration with telehealth companies so that there could be access to Wegovy as the compounding is winding down.” This initiative is designed to support patients transitioning from compounded medicines, which were in high demand during Wegovy’s supply shortages.

Market Response and Pricing Strategy

Following the announcement, shares in Hims & Hers rose by 23%, while Novo Nordisk’s stock saw a 4% increase. Wegovy is now available through NovoNordisk’s direct-to-consumer pharmacy, NovoCare, at a cost of $499 per month for those without insurance, which is significantly below the usual list price.

However, pricing may vary among telehealth companies as they include additional services in their packages. Hims & Hers plans to offer various dosages along with extensive patient support for $599 per month, a value-added service approach according to CEO Andrew Dudum.

Impact of Regulatory Changes

In light of regulatory restrictions on compounded versions of Wegovy, Novo Nordisk is positioned to gain a competitive advantage. Larger pharmacies must cease marketing unauthorized versions of the drug, while smaller pharmacies can still produce compounded forms under specific medical circumstances. This strong regulatory framework is set to benefit branded products like Wegovy, ensuring quality and patient safety.

Broader Implications for Obesity Treatment

This initiative highlights a growing trend toward integrating telehealth in the prescription process, making treatments more accessible for patients with limited insurance options. As Zach Reitano, CEO of Ro, stated, “Adding Novo Nordisk’s FDA-approved treatments at the best available cash price will help more patients nationwide get the obesity care they need to achieve their goals.”

With this strategic move, Novo Nordisk aims not only to improve patient outcomes but also to set a benchmark for accessibility in the healthcare sector.